To evaluate whether ACE2-Fc is valuable for combining with neutralizing antibodies, we used three potent neutralizing antibodies, 13A12, 8G9, and 10D4, which originated from COVID-19 convalescent patients [28]. The gene discussed is ACE2; the disease is COVID-19.